3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
3
Unknown
2
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Triple Negative Breast Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Melanoma
1
Lung Neoplasms
1
Lung Diseases
1
Locally Advanced Non-small Cell Lung Cancer
1
Liver Neoplasms
1
Liver Diseases
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Carcinoma, Hepatocellular
1
Brain Neoplasms
1
Adenocarcinoma of Lung
1
Adenocarcinoma
1
Interventions
Radiosurgery
10
Temozolomide
6
Magnetic Resonance Spectroscopy
6
pembrolizumab
3
Trastuzumab
3
Radiation
3
fluciclovine F-18
2
cabazitaxel
2
Surgical Procedures, Operative
2
Specimen Handling
2
Radiotherapy
2
Magnetic Resonance Imaging
2
Erlotinib Hydrochloride
2
Carboplatin
2
Bevacizumab
2
Aminolevulinic Acid
2
tucatinib
1
thymoglobulin
1
tepotinib
1
temsirolimus
1
sodium thiosulfate
1
ribociclib
1
pazopanib
1
patritumab deruxtecan
1
palbociclib
1
osimertinib
1
neratinib
1
lenvatinib
1
irinotecan sucrosofate
1
gancotamab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Brain Neoplasms
×
Immunotherapy
×
Clear all
NCT04650490
2023-03-02
STICk-IM-NSCLC
Duke University
Phase 2
Withdrawn